Adrenalina
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
ADRENALINA: Drug Repurposing Evaluation Report
One-Sentence Summary
Adrenalina (Adrenaline/Epinephrine) is a well-known endogenous catecholamine widely used in emergency medicine for anaphylaxis, cardiac arrest, and severe asthma. The TxGNN model did not generate any predicted new indications for this drug, and the evidence pack contains significant data gaps across regulatory, safety, and mechanistic domains. No repurposing candidates are available for evaluation at this time.
Quick Overview
| Item | Content |
|---|---|
| Drug Name (INN) | ADRENALINA (Adrenaline / Epinephrine) |
| DrugBank ID | Not available |
| Original Indication | Not listed in evidence pack |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (No predictions, no supporting studies) |
| Taiwan Market Status | ❌ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why Are There No Predictions?
Adrenalina (Epinephrine) is an endogenous catecholamine that acts on α- and β-adrenergic receptors, producing widespread sympathomimetic effects including bronchodilation, vasoconstriction, and cardiac stimulation. It is a cornerstone of emergency medicine globally.
However, the TxGNN model returned zero predicted indications for this compound. Several factors may explain this:
- Knowledge graph coverage: The drug entry may be incomplete or absent in the knowledge graph used by TxGNN. The DrugBank ID was not resolved in the evidence pack, which could indicate a mapping failure between the INN "ADRENALINA" (the Italian/Latin form) and the standard entry for Epinephrine (DrugBank: DB00668).
- Broad existing indication profile: Epinephrine already has a very broad set of approved indications (anaphylaxis, cardiac arrest, local anaesthesia adjunct, open-angle glaucoma, septic shock, croup, asthma). The model may not have identified additional novel indications beyond this already extensive list.
- Data gaps: The evidence pack is missing the mechanism of action (MOA) field, original indications, and the DrugBank ID — all of which are critical inputs for generating meaningful predictions.
Clinical Trial Evidence
No predicted indications were generated by TxGNN, therefore no targeted clinical trial search was performed for repurposing candidates.
Literature Evidence
No predicted indications were generated by TxGNN, therefore no targeted literature search was performed for repurposing candidates.
Taiwan Market Information
Adrenalina returned 0 authorizations from the TFDA query. This may reflect:
- A name-matching issue ("ADRENALINA" is the Italian/Latin INN; the TFDA may list it under "Epinephrine" or the Chinese name 腎上腺素)
- The drug may be marketed under combination products or brand names not captured by the INN search
Recommendation: Re-query TFDA using "Epinephrine", "腎上腺素", or "ADRENALINE" to confirm market status.
Safety Considerations
No safety data (warnings, contraindications, or drug-drug interactions) was retrieved for this evidence pack. This is classified as a Blocking data gap.
Please refer to the package insert for safety information. For a drug as widely used as Epinephrine, comprehensive safety data is available in standard pharmacological references and should be obtained before any repurposing evaluation proceeds.
Data Gaps Summary
The following critical data gaps were identified and must be resolved before proceeding:
| Gap ID | Category | Item | Severity | Recommended Remediation |
|---|---|---|---|---|
| DG001 | Drug Level | TFDA Package Insert Warnings/Contraindications | Blocking | Download and parse package insert PDF from TFDA website |
| DG002 | Drug Level | Mechanism of Action (MOA) | High | Query DrugBank API using DB00668 (Epinephrine) |
| — | Drug Level | DrugBank ID mapping | High | Map "ADRENALINA" → Epinephrine (DB00668) |
| — | Prediction | TxGNN predicted indications | High | Re-run TxGNN with correct DrugBank ID and standardized drug name |
| — | Regulatory | TFDA market authorization | Medium | Re-query using alternative names (Epinephrine, 腎上腺素, ADRENALINE) |
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence pack for ADRENALINA contains no TxGNN predictions and has multiple blocking data gaps. The most likely root cause is a drug name mapping failure — "ADRENALINA" (Italian INN) was not correctly resolved to its DrugBank entry (Epinephrine, DB00668), which cascaded into empty results across all downstream modules.
To proceed, the following is needed:
- Resolve drug identity mapping: Confirm ADRENALINA = Epinephrine = DB00668, and re-run the pipeline with the correct DrugBank ID
- Re-query TFDA: Search under "Epinephrine", "ADRENALINE", and "腎上腺素" to capture existing Taiwan market authorizations
- Re-run TxGNN prediction: With the correctly mapped drug entity in the knowledge graph
- Obtain safety data: Download and parse the TFDA package insert once the correct product is identified
- Obtain MOA data: Pull mechanism of action from DrugBank (adrenergic receptor agonist — α1, α2, β1, β2, β3)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.